PTC Therapeutics PTCT Liability Sale Of Future Royalties Current
Liability Sale Of Future Royalties Current at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept ptct:LiabilitySaleOfFutureRoyaltiesCurrent.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's liability sale of future royalties current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's liability sale of future royalties current?
- PTC Therapeutics (PTCT) reported liability sale of future royalties current of $305.04M in Q1 2026.
- How has PTC Therapeutics's liability sale of future royalties current changed year-over-year?
- PTC Therapeutics's liability sale of future royalties current increased by 22.9% year-over-year, from $248.24M to $305.04M.
- What is the long-term trend for PTC Therapeutics's liability sale of future royalties current?
- Over 5 years (2020 to 2025), PTC Therapeutics's liability sale of future royalties current has grown at a 68.2% compound annual growth rate (CAGR), from $21.02M to $283M.
- What does liability sale of future royalties current mean?
- This represents the portion of obligations arising from the monetization of future royalty streams that is due within the next twelve months. It reflects a financing strategy where the company receives upfront capital in exchange for a portion of future revenue generated by specific products. Investors track this to understand the impact of royalty-based financing on short-term cash flow and future revenue retention.